Condition
Drug Side Effect
Total Trials
6
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Unknown3
Recruiting2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04659343Recruiting
TDM for Optimized Outcome in Patients With mRCC.
NCT06498167Recruiting
Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)
NCT05144295Phase 3Completed
Lubiprostone for Functional Constipation in the Under 18 Years Patients
NCT05376943Unknown
Possible Differences in HCC Course Depending on DAA Treatment
NCT04747678Unknown
Adverse Effects of Ivermectin Used in Egypt During COVID-19
NCT03084952Phase 2Unknown
Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients
Showing all 6 trials